Odontogenic myxofibroma with HMGA2 overexpression and HMGA2 rearrangement.
Finally, in a number of lipomas, HMGA2/LPP and HMGA2 are coexpressed, and HMGA2 augments the transactivation functions of HMGA2/LPP.
Oncogenic HMGA2: short or small?
HMGA2 is a driver of tumor metastasis.
In vivo modulation of HMGA2 expression.
RT-PCR confirmed transcriptional upregulation of HMGA2 only in tumors with HMGA2 rearrangements.
The TCEA1-PLAG1, HMGA2-FHIT, and HMGA2-NFIB fusion transcripts were not detected.
Hmga2 promoter analysis in transgenic mice.
Fusion of the HMGA2 and NFIB genes in lipoma.
The gene HMGA2 is the main target in these aberrations.
Fusion of HMGA2 to COG5 in uterine leiomyoma.
HMGA2, microRNAs, and stem cell aging.
Expression of HMGA2-LPP and LPP-HMGA2 fusion genes in lipoma: identification of a novel type of LPP-HMGA2 transcript in four cases.
HMGA2 protein expression was detected in 100% of lipomas with HMGA2 rearrangement and 48% of lipomas without HMGA2 rearrangement.
Trisomy of chromosome 12, where HMGA2 is located, and/or amplification of the HMGA2 gene locus account for the HMGA2 overexpression in most human prolactinomas.
The overexpression of HMGA2 may be caused by a cryptic chromosomal aberration affecting either the cytogenetically unaltered HMGA2 allele or HMGA2 regulators elsewhere.
There were 23 cases (22.5%) expressing HMGA2/LPP, 2 cases (1.9%) expressing HMGA2/RDC1 and no cases of HMGA2/NFIB expression (0%).
HMGA2 gene amplification and overexpression in human prolactinomas and the development of pituitary adenomas in HMGA2 transgenic mice showed that HMGA2 plays a crucial role in pituitary tumorigenesis.
HMGA2 was highly overexpressed in 100% of well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS), all with HMGA2 amplification, and 100% of lipomas with HMGA2 rearrangement.
Here we deciphered the role of the high-mobility-group AT-hook protein 2 (HMGA2) during lung development by analyzing the lung of Hmga2-deficient mice (Hmga2(-/-)).
HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia.
HMGA1 and HMGA2 protein expression in mouse spermatogenesis.
Molecular dissection of the architectural transcription factor HMGA2.
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia.
HMGA2 is expressed in an allele-specific manner in human lipomas.
Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.
Abnormally high HMGA2 microRNA was found in myelofibrosis granulocytes.
Clinicopathological features of lipomas with gene fusions involving HMGA2.
HMGA2 participates in transformation in human lung cancer.
In chromosome 12, the breakpoints clustered to the region of HMGA2.
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.
HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma.
There was no correlation between HMGA2 expression and differentiation/laterality.
HMGA1 and HMGA2 rearrangements in mass-forming endometriosis.
Knockdown of HMGA2 inhibited 3T3-L1 differentiation.
HMGA2 overexpression in non-small cell lung cancer.
HMGA2 is expressed in moss protonema and it localises to the cell nucleus.
HMGA2 expression in a canine model of prostate cancer.
Ten lipomas (10%) revealed both HMGA2-LPP and LPP-HMGA2 fusion transcripts, nine (9%) only HMGA2-LPP, and three (3%) only LPP-HMGA2.
Critical role of the HMGA2 gene in pituitary adenomas.
An intragenic rearrangement of HMGA2 is not necessary for lipoma formation.
HMGA2 is confirmed to be associated with human adult height.
Overexpression of HMGA2 is common in uterine leiomyomas (ULM).
Suppression of nonhomologous end joining repair by overexpression of HMGA2.
HMGA2: A pituitary tumour subtype-specific oncogene?
The HMGA2 gene encodes a protein that alters chromatin structure.
Additionally, comparative HMGA2 protein expression was analysed by immunohistochemistry.
An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis.
Altogether, these data suggest that HMGA2 is an upstream activator of PLAG1.
HMGA2 and high-grade serous ovarian carcinoma.
HMGA2 expression was unrelated to chemotherapy response or survival.
BMP4 increases expression of HMGA2 in mesenchymal stem cells.
HMGA2 is the main target of clonal aberrations encountered in lipomas.
Both of them had no effect on the level of HMGA2 mRNA.
The transcription of let-7 inversely correlated with HMGA2 protein.
HMGA2, a let-7d target, was localized by immunohistochemistry.
HMGA2 was increased in alveolar epithelial cells of IPF lungs.
HMGA2, an oncofetal protein, is found to be overexpressed in ovarian cancer.
The expression of HMGA2 varies strongly among colon carcinomas.
The HMGA2 gene SNP was significantly associated with tall stature.
Indeed, HMGA2 was overexpressed in many different kinds of tumors.
However, the mechanisms regulating HMGA2 expression remain elusive.
Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2.
Hmga2 regulates self-renewal of retinal progenitors.
qRT-PCR data showed similar results in FFPE tissues: the sensitivity was 84.2% for HMGA2, 85.7% for IMP3, and 94.7% for HMGA2+IMP3; the specificity was 96.9% for HMGA2, 91.2% for IMP3, and 90.6% ...
[Research progress of relationship between HMGA2 and tumors].
However, the interference of the expression of HMGA2 resulted in opposite results.
No structural alterations were observed at the HMGA2 locus in either primary rat leiomyomas or leiomyoma-derived cell lines that expressed HMGA2.
As HMGA2 null mice showed a great reduction in fat tissue, a positive role of the HMGA2 gene in adipocytic cell proliferation is proposed.
Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2.
HMGA2 locus rearrangement was associated with overexpression of an HMGA2 mRNA that lacked a carboxy-terminal tail.
Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2.
These data identify the cyclin A gene as a cellular target for HMGA2 and, for the first time, suggest a mechanism for HMGA2-dependent cell cycle regulation.